The ONSEMBLE phase 2 open-label randomized trial for the second line treatment of patients with KRAS/NRAS mutated metastatic colorectal cancer (MCRC) is designed to
Demonstrate onvansertib’s contribution to SoC
Confirm optimal dosing
Demonstrate onvansertib’s contribution to SoC
Operate with capital efficiency
Enrollment Criteria
ENDPOINTS
Primary
Objective Response Rate: CR + PR
Key Secondary
Progression-Free Survival
Other Secondary
Disease Control Rate: CR + PR + SD
Duration of Response: DoR
Overall Survival: OS
Reduced MAF association with ORR, PFS, DCR, DoR, OS